Brief: Ngm Biopharmaceuticals Inc- Merck Has Verbally Notified The Company That It Will Not Exercise Its Option To License Ngm621 And Its Related Compounds
20/12/2022 21:13
Dec 20 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIOPHARMACEUTICALS INC- MERCK HAS VERBALLY NOTIFIED
THE
COMPANY THAT IT WILL NOT EXERCISE ITS OPTION TO LICENSE NGM621
AND ITS RELATED COMPOUNDS
* NGM BIOPHARMACEUTICALS- MERCK TO NOT EXERCISE RELATED
OPHTHALMOLOGY BUNDLE OPTION; OPTIONS TO EXPIRE UNEXERCISED ON
NGM621 OPTION EXPIRATION DATE
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors